文献速递中医内科中药与中成药合理使用

红紫素经雌激素受体α依赖的PI3K/AKT信号改善化疗所致血小板减少

Purpurin Alleviates Chemotherapy‐Induced Thrombocytopenia Through Estrogen Receptor α Dependent Phosphoinositide 3‐Kinase/Protein Kinase B Signalling
RSS 订阅 · Phytotherapy Research · 2026-10-30

本研究探讨茜草中羟基蒽醌红紫素对环磷酰胺所致血小板减少的恢复作用及ESR1-PI3K/AKT信号参与。在K562和Meg-01细胞、斑马鱼及小鼠模型中,红紫素促进巨核细胞分化与血小板恢复,且该作用可被ESR1或PI3K抑制所减弱。

要点

  • 红紫素在2.5–10 μM无细胞毒浓度下促进巨核细胞分化和多倍体化。
  • 红紫素恢复环磷酰胺处理小鼠的血小板计数和止血功能。
  • ESR1-PI3K/AKT信号通路参与红紫素促巨核细胞生成作用。

核心结论

  • 红紫素通过ESR1相关的PI3K/AKT信号促进巨核细胞生成和血小板恢复,可作为化疗所致血小板减少的天然产物先导化合物进一步评估。

研究设计与样本

  • 研究在K562和Meg-01巨核细胞分化模型、Tg(itga2b:eGFP)斑马鱼和环磷酰胺诱导的血小板减少小鼠中评估红紫素。
  • 采用计算靶点预测、药物亲和反应靶点稳定性(DARTS)分析和ESR1及PI3K的药理学抑制进行机制验证。

主要发现

  • 在2.5–10 μM不引起可检测细胞毒性的浓度下,红紫素增加CD41+CD42b+细胞、巨核细胞倍体、F-actin重塑及NF-E2、GATA1、RUNX1和FOSB表达。
  • 红紫素增加斑马鱼血栓细胞丰度,并恢复环磷酰胺处理小鼠的血小板计数、巨核细胞成熟和止血功能。
  • DARTS实验中红紫素增加ESR1对蛋白水解的抗性;药理学抑制ESR1或PI3K减弱红紫素诱导的分化和PI3K/AKT磷酸化。

临床怎么用

  • 红紫素作为天然产物先导化合物,需进一步开展遗传靶点验证、药代动力学表征及荷瘤模型评估后方可考虑临床转化。

局限性

  • 研究仅采用环磷酰胺诱导的血小板减少模型,未在荷瘤模型中评估。
  • 尚需遗传靶点验证和药代动力学表征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schematic overview of the in vitro and in vivo evaluation of purpurin in promoting MK maturation and platelet production, through ESR1/PI3K/AKT. ABSTRACT Chemotherapy-induced thrombocytopenia (CIT) increases bleeding risk and compromises chemotherapy delivery. Purpurin, a hydroxyanthraquinone found in Rubia cordifolia L., has not been examined as a regulator of megakaryopoiesis. We investigated whether purpurin restores platelet production after cyclophosphamide (CTX) exposure and examined the involvement of estrogen receptor α (ESR1)–phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signalling. Purpurin was evaluated in K562 and Meg-01 megakaryocytic differentiation models, Tg(itga2b:eGFP) zebrafish, and CTX-induced thrombocytopenic mice. Megakaryocyte (MK) differentiation, DNA ploidy, cytoskeletal remodelling, platelet recovery, and haemostatic function were assessed. Computational target prediction was used for hypothesis generation, followed by drug affinity responsive target stability analysis and pharmacological inhibition of ESR1 and PI3K. At concentrations that did not cause detectable cytotoxicity (2.5–10 μM), purpurin increased CD41+CD42b+ cells, MK ploidy, F-actin remodelling, and expression of NF-E2, GATA1, RUNX1, and FOSB. Purpurin increased thrombocyte abundance in zebrafish and restored platelet counts, MK maturation, and haemostatic function in CTX-treated mice. Purpurin increased the resistance of ESR1 to proteolysis in the drug affinity responsive target stability (DARTS) assay. Pharmacological inhibition of ESR1 or PI3K attenuated purpurin-induced differentiation and PI3K/AKT phosphorylation. These findings support the involvement of ESR1-associated PI3K/AKT signalling through which purpurin promotes megakaryopoiesis and platelet recovery. Purpurin warrants further evaluation as a natural-product lead for CIT, including genetic target validation, pharmacokinetic characterization, and assessment in tumour-bearing models.

来源:Phytotherapy Research,查看原文。版权归原作者所有。

引用

  1. Phytotherapy Research:Purpurin Alleviates Chemotherapy‐Induced Thrombocytopenia Through Estrogen Receptor α Dependent Phosphoinositide 3‐Kinase/Protein Kinase B Signalling

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。